Vortioxetine 10-20 mg
DrugOther names: Brintellix®, Lu AA21004
NCT Number: NCT02279953
To assess the efficacy of vortioxetine (10 to 20 mg/day) as adjunctive treatment to stable selective serotonin reuptake inhibitor (SSRI) dose versus stable SSRI monotherapy on cognitive performance (focusing on the aspect concerning speed of processing, executive functioning and attention) in patients who are in partial or full remission from their Major Depressive Episode (MDE).
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 3
EE001, Tallinn, Estonia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other protocol-defined inclusion and exclusion criteria may apply.
Other names: Brintellix®, Lu AA21004
escitalopram, citalopram or sertraline
Time frame: Baseline to Week 8
Time frame: Baseline to Week 8
Time frame: Baseline to Week 8
Time frame: Baseline to Week 8
Time frame: Baseline to Week 8
Time frame: Baseline to Week 8
Time frame: Baseline to Week 8
Time frame: Baseline to Week 8
Time frame: Baseline to Week 8
Time frame: Baseline to Week 8
Time frame: Baseline to Week 8
Time frame: Week 8
Time frame: Baseline to Week 8
Time frame: Baseline to Week 12
Time frame: Baseline to Week 8
H. Lundbeck A/S
Industry
An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04276259
Behavior, Behavioral Symptoms
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06001346
Behavior, Behavioral Symptoms
Ames, Iowa, United States
View Trial DetailsNCT06266390
Behavior, Behavioral Symptoms
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06267846
Behavior, Behavioral Symptoms
Little Rock, Arkansas, United States
View Trial Details